Thyroid function and ultrasound surveillance in childhood cancer survivors (CCS): a position paper of the Italian Society of Pediatric Endocrinology and Diabetology (ISPED).
| Title: | Thyroid function and ultrasound surveillance in childhood cancer survivors (CCS): a position paper of the Italian Society of Pediatric Endocrinology and Diabetology (ISPED). |
|---|---|
| Authors: | Tuli G; Department of Pediatric Endocrinology, Regina Margherita Children's Hospital, Turin, Italy. gerdi.tuli@unito.it.; Department of Pediatrics, University of Turin, Turin, Italy. gerdi.tuli@unito.it.; Piazza Polonia 94, Torino, 10126, Italy. gerdi.tuli@unito.it.; Calcaterra V; Pediatric Department, Buzzi Children's Hospital, Milan, Italy.; Department of Internal Medicine, University of Pavia, Pavia, Italy.; Di Mase R; Pediatric Endocrinology Unit, Department of Mother and Child University Hospital Federico II Naples, Naples, Italy.; Vigone MC; Endocrine Unit, Department of Pediatrics, IRCCS Ospedale San Raffaele, Milan, Italy.; Gastaldi R; Pediatric Endocrinology Unit, Department of Pediatrics, IRCCS Istituto Giannina Gaslini, Genoa, Italy.; Ferrigno R; Neuro-Endocrine Diseases and Obesity Unit, Department of Neurosciences, Santobono-Pausilipon Children's Hospital, Naples, Italy.; Improda N; Neuro-Endocrine Diseases and Obesity Unit, Department of Neurosciences, Santobono-Pausilipon Children's Hospital, Naples, Italy.; Klain A; Neuro-Endocrine Diseases and Obesity Unit, Department of Neurosciences, Santobono-Pausilipon Children's Hospital, Naples, Italy.; Licenziati MR; Neuro-Endocrine Diseases and Obesity Unit, Department of Neurosciences, Santobono-Pausilipon Children's Hospital, Naples, Italy.; Pellino V; Neuro-Endocrine Diseases and Obesity Unit, Department of Neurosciences, Santobono-Pausilipon Children's Hospital, Naples, Italy.; Aversa T; Department of Human Pathology of Adulthood and Childhood, University of Messina, Messina, Italy.; Pediatric Unit 'G. Martino', University Hospital, Messina, Italy.; Pepe G; Department of Human Pathology of Adulthood and Childhood, University of Messina, Messina, Italy.; Pediatric Unit 'G. Martino', University Hospital, Messina, Italy.; Ortolano R; Department Hospital of Woman and Child, Pediatric Unit, IRCCSAzienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.; Capalbo D; Pediatric Endocrinology Unit, Department of Translational Medical Sciences, University Federico II, Naples, Italy.; Urbano F; University Pediatrics Unit, Pediatric Hospital 'Giovanni XXIII', University Hospital Consortium Policlinico, Bari, Italy.; Di Frenna M; Pediatric Department, Buzzi Children's Hospital, Milan, Italy.; Cavarzere P; Pediatric B Division, Department of Pediatrics, University Hospital of Verona, Verona, Italy.; Penta L; Department of Pediatrics, University of Perugia, Perugia, Italy.; Munarin J; Department of Pediatric Endocrinology, Regina Margherita Children's Hospital, Turin, Italy.; Department of Pediatrics, University of Turin, Turin, Italy.; Vincenzi G; Endocrine Unit, Department of Pediatrics, IRCCS Ospedale San Raffaele, Milan, Italy.; Molinari S; Department of Pediatrics, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.; Faienza MF; Pediatric Unit, Department of Precision and Regenerative Medicine andIonian Area, University of Bari 'A. Moro', Bari, Italy.; Street ME; Department of Medicine and Surgery, Unit of Paediatrics, University of Parma, University Hospital of Parma, Parma, Italy.; Salerno M; Pediatric Endocrinology Unit, Department of Translational Medical Sciences, University Federico II, Naples, Italy.; Wasniewska M; Department of Human Pathology of Adulthood and Childhood, University of Messina, Messina, Italy.; Pediatric Unit 'G. Martino', University Hospital, Messina, Italy.; Cherubini V; Pediatric Endocrinology and Diabetology Unit, Azienda Ospedaliero Universitaria delle Marche, G. Salesi Hospital, Ancona, Italy.; Cassio A; University of Bologna, Bologna, Italy. |
| Source: | Journal of endocrinological investigation [J Endocrinol Invest] 2026 Apr 15. Date of Electronic Publication: 2026 Apr 15. |
| Publication Model: | Ahead of Print |
| Publication Type: | Journal Article; Review |
| Language: | English |
| Journal Info: | Publisher: Springer Country of Publication: Italy NLM ID: 7806594 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1720-8386 (Electronic) Linking ISSN: 03914097 NLM ISO Abbreviation: J Endocrinol Invest Subsets: MEDLINE |
| Imprint Name(s): | Publication: 2014- : Berlin : Springer; Original Publication: Milano, Published for the Italian Society of Endocrinology by Editrice Kurtis. |
| Competing Interests: | Declarations. Conflict of interest: All authors have nothing to declare. |
| References: | Lebbink CA, Waguespack SG, van Santen HM (2021) Thyroid Dysfunction and Thyroid Cancer in Childhood Cancer Survivors: Prevalence, Surveillance and Management. Front Horm Res 54:140–153. (PMID: 3369023710.1159/000513805); van Santen HM, Thonissen NM, de Kraker J et al (2005) Changes in thyroid hormone state in children receiving chemotherapy. Clin Endocrinol (Oxf) 62:250–257. (PMID: 1567020410.1111/j.1365-2265.2005.02210.x); Massart C, Le Tellier C, Lucas C et al (1992) Effects of cisplatin on human thyrocytes in monolayer or follicle culture. J Mol Endocrinol 8:243–248. (PMID: 132163610.1677/jme.0.0080243); Hamnvik OP, Larsen PR, Marqusee E (2011) Thyroid dysfunction from antineoplastic agents. J Natl Cancer Inst 103:1572–1587. (PMID: 22010182320604010.1093/jnci/djr373); Torino F, Barnabei A, Paragliola R et al (2013) Thyroid dysfunction as an unintended side effect of anticancer drugs. Thyroid 23:1345–1366. (PMID: 2375088710.1089/thy.2013.0241); Cattoni A, Molinari S, Gaiero A et al (2022) Thyroid Disorders Following Hematopoietic Stem Cell Transplantation in Childhood: Impact of Conditioning Regimen on Thyroid Dysfunction, Volume Changes, and Occurrence of Nodules. Transplant Cell Ther 28:506.e1-506.e12.; van der Leij S, Lebbink CA, Lentjes EG et al (2023) Thyroid dysfunction during treatment with systemic antineoplastic therapy for childhood cancer: A systematic review. Crit Rev Oncol Hematol 184:103958. (PMID: 3690736310.1016/j.critrevonc.2023.103958); Basolo A, Matrone A, Elisei R et al (2022) Effects of tyrosine kinase inhibitors on thyroid function and thyroid hormone metabolism. Semin Cancer Biol 79:197–202. (PMID: 3347672210.1016/j.semcancer.2020.12.008); Pani F, Atzori F, Baghino G et al (2015) Thyroid Dysfunction in Patients with Metastatic Carcinoma Treated with Sunitinib. Is Thyroid Autoimmun Involved? Thyroid 25:1255–1261.; Tomer Y, Blackard JT, Akeno N (2007) Interferon alpha treatment and thyroid dysfunction. Endocrinol Metab Clin North Am 36:1051–1066. (PMID: 17983936213478710.1016/j.ecl.2007.07.001); Hauschild A, Gogas H, Tarhini A et al (2008) Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer 112:982–994. (PMID: 1823645910.1002/cncr.23251); Ribas A, Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade. Science 359:1350–1355. (PMID: 29567705739125910.1126/science.aar4060); Wright JJ, Powers AC, Johnson DB (2021) Endocrine toxicities of immune checkpoint inhibitors. Nat Rev Endocrinol 17:389–399. (PMID: 33875857876905510.1038/s41574-021-00484-3); Iwama S, Kobayashi T, Yasuda Y et al (2022) Immune checkpoint inhibitor-related thyroid dysfunction. Best Pract Res Clin Endocrinol Metab 36:101660. (PMID: 3550126310.1016/j.beem.2022.101660); Tawbi HA, Burgess M, Bolejack V et al (2017) Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol 18:1493–1501. (PMID: 28988646793902910.1016/S1470-2045(17)30624-1); Geoerger B, Zwaan CM, Marshall LV et al (2020) Atezolizumab for children and young adults with previously treated solid tumors, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1–2 study. Lancet Oncol 21:134–144. (PMID: 3178025510.1016/S1470-2045(19)30693-X); Geoerger B, Kang HJ, Yalon-Oren M et al (2020) Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumor or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial. Lancet Oncol 21:121–133. (PMID: 3181255410.1016/S1470-2045(19)30671-0); Davis KL, Fox E, Merchant MS et al (2020) Nivolumab in children and young adults with relapsed or refractory solid tumors or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1–2 trial. Lancet Oncol 21:541–550. (PMID: 32192573725554510.1016/S1470-2045(20)30023-1); Dunkel IJ, Doz F, Foreman NK et al (2023) Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: Safety, efficacy, biomarker, and pharmacokinetics. Neuro Oncol 25:1530–1545. (PMID: 368082851039881110.1093/neuonc/noad031); Yasuda Y, Iwama S, Sugiyama D et al (2021) CD4(+) T cells are essential for the development of destructive thyroiditis induced by anti-PD-1 antibody in thyroglobulin-immunized mice. Sci Transl Med 13:eabb7495. (PMID: 3398057710.1126/scitranslmed.abb7495); Oeffinger KC, Mertens AC, Sklar CA et al (2006) Childhood Cancer Survivor Study. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 355:1572–1582. (PMID: 1703565010.1056/NEJMsa060185); Nandagopal R, Laverdière C, Mulrooney D et al (2008) Endocrine late effects of childhood cancer therapy: a report from the Children’s Oncology Group. Horm Res 69:65–74. (PMID: 18059086); Rizzo JD, Wingard JR, Tichelli A et al (2006) Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transpl 12:138–151. (PMID: 10.1016/j.bbmt.2005.09.012); Husebye ES, Castinetti F, Criseno S et al (2022) Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. Eur J Endocrinol 187:G1–G21. (PMID: 36149449964179510.1530/EJE-22-0689); Vejbjerg P, Knudsen N, Perrild H et al (2006) The association between hypoechogenicity or irregular echo pattern at thyroid ultrasonography and thyroid function in the general population. Eur J Endocrinol 155:547–552. (PMID: 1699065310.1530/eje.1.02255); Rago T, Chiovato L, Grasso L et al (2001) Thyroid ultrasonography as a tool for detecting thyroid autoimmune diseases and predicting thyroid dsfunction in apparently healthy subjects. J Endocrinol Invest 24:763–769. (PMID: 1176504510.1007/BF03343925); Rotondi M, Coperchini F, Magri F et al (2014) Serum-negative autoimmune thyroiditis: what’s in a name? J Endocrinol Invest 37:589–591. (PMID: 2478954210.1007/s40618-014-0083-8); Rose SR, Lustig RH, Pitukcheewanont P et al (1999) Diagnosis of hidden central hypothyroidism in survivors of childhood cancer. J Clin Endocrinol Metab 84:4472–4479. (PMID: 10599705); Waguespack SG (2019) Thyroid Sequelae of Pediatric Cancer Therapy. Horm Res Paediatr 91:104–117. (PMID: 3054101010.1159/000495040); Rose SR, Horne VE, Howell J et al (2016) Late endocrine effects of childhood cancer. Nat Rev Endocrinol 12:319–336. (PMID: 2703298210.1038/nrendo.2016.45); Surveillance E, Program ER, National Cancer Institute (2024). SEER Cancer Statistics Review 1975–2018. Posted April 15, 2021. Accessed June 27. https://seer.cancer.gov/csr/1975_2018/.; Bhakta N, Liu Q, Ness KK et al (2017) The cumulative burden of surviving childhood cancer. Lancet 390:2569–2582. (PMID: 28890157579823510.1016/S0140-6736(17)31610-0); Mostoufi-Moab S, Seidel K, Leisenring WM et al (2016) Endocrine abnormalities in aging survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. J Clin Oncol 34:3240–3247. (PMID: 27382091502454610.1200/JCO.2016.66.6545); Inskip PD, Veiga LHS, Brenner AV, Shet al (2018) Hypothyroidism after Radiation Therapy for Childhood Cancer: A Report from the Childhood Cancer Survivor Study. Radiat Res 190:117–132. (PMID: 29763379616183810.1667/RR14888.1); Inskip PD, Veiga LHS, Brenner AV et al (2019) Hyperthyroidism after radiation therapy for childhood cancer: A report from the Childhood Cancer Survivor Study. Int J Radiat Oncol Biol Phys 104:415–424. (PMID: 30769174681823110.1016/j.ijrobp.2019.02.009); Boomsma MJ, Bijl HP, Langendijk JA (2011) Radiation-induced hypothyroidism in head and neck cancer patients: a systematic review. Radiother Oncol 99:1–5. (PMID: 2145946810.1016/j.radonc.2011.03.002); Milano MT, Vargo JA, Yorke ED et al (2024) Primary Hypothyroidism in Childhood Cancer Survivors Treated With Radiation Therapy: A PENTEC Comprehensive Review. Int J Radiat Oncol Biol Phys 119:482–493. (PMID: 3381094810.1016/j.ijrobp.2021.02.001); Chow JCH, Cheung KM, Cheung GTC et al (2022) Dose-volume predictors of post-radiation primary hypothyroidism in head and neck cancer: A systematic review. Clin Transl Radiat Oncol 33:83–92. (PMID: 351280878807951); Vogelius IR, Bentzen SM, Maraldo MV et al (2011) Risk factors for radiation-induced hypothyroidism: a literature-based meta-analysis. Cancer 117:5250–5260. (PMID: 2156738510.1002/cncr.26186); Zhou L, Chen J, Tao C-J et al (2021) Research progress of radiation-induced hypothyroidism in head and neck cancer. J Cancer 12:451–459. (PMID: 33391441773899410.7150/jca.48587); Children’s Oncology Group. Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers: version 6.0 (2023) (October http://www.survivorshipguidelines.org.; Bhatia S, Tonorezos ES, Landier W (2023) Clinical Care for People Who Survive Childhood Cancer: A Review. JAMA 330:1175–1186. (PMID: 3775087610.1001/jama.2023.16875); Clement SC, van Rijn RR, van Eck-Smit BLF et al (2015) Long-term efficacy of current thyroid prophylaxis and future perspectives on thyroid protection during 131I-metaiodobenzylguanidine treatment in children with neuroblastoma. Eur J Nucl Med Mol Imaging 42:706–715. (PMID: 2551205610.1007/s00259-014-2967-4); van Santen HM, de Kraker J, van Eck BLF et al (2002) High incidence of thyroid dysfunction despite prophylaxis with potassium iodide during 131I-meta-iodobenzylguanidine treatment in children with neuroblastoma. Cancer 94:2081–2089. (PMID: 1193291310.1002/cncr.10447); Quach A, Ji L, Mishra V et al (2011) Thyroid and hepatic function after high-dose 131I-metaiodobenzylguanidine (131I-MIBG) therapy for neuroblastoma. Pediatr Blood Cancer 56:191–201. (PMID: 2083077510.1002/pbc.22767); Clement SC, Tytgat GAM, van Trotsenburg ASP et al (2022) Thyroid function after diagnostic 123I-metaiodobenzylguanidine in children with neuroblastic tumors. Ann Nucl Med 36:579–585. (PMID: 35499668913283510.1007/s12149-022-01743-7); Persani L, Brabant G, Dattani M et al (2018) European thyroid association (ETA) guidelines on the diagnosis and management of Central hypothyroidism. Eur Thyroid J 7:225–237. (PMID: 30374425619877710.1159/000491388); Rose SR, Schreiber RE, Kearney NS et al (2004) Hypothalamic dysfunction after chemotherapy. J Pediatr Endocrinol Metab 17:55–66. (PMID: 1496002210.1515/JPEM.2004.17.1.55); Baronio F, Battisti L, Radetti G (2011) Central hypothyroidism following chemotherapy for acute lymphoblastic leukemia. J Pediatr Endocrinol Metab 24:903–906. (PMID: 2230884010.1515/JPEM.2011.407); Amy L, Wanaguru DJ, Tait et al (2022) Central hypothyroidism after chemotherapy in childhood cancer survivors: a single centre series. Acta Oncol 12:1477–1480.; van Iersel L, Li Z, Srivastava DK et al (2019) Hypothalamic-Pituitary Disorders in Childhood Cancer Survivors: Prevalence, Risk Factors and Long-Term Health Outcomes. J Clin Endocrinol Metab 104:6101–6115. (PMID: 31373627729613010.1210/jc.2019-00834); Jin HY, Lee JA, Park M et al (2023) Characteristics and clinical course of thyroid abnormalities arisen in long term survivors of childhood cancer. BMC Pediatr 23:124. (PMID: 369323421002437910.1186/s12887-023-03900-x); Zhang Y-X, Shen C-H, Lai Q-L et al (2016) Effects of antiepileptic drug on thyroid hormones in patients with epilepsy: a meta-analysis. Seizure 35:72–79. (PMID: 2680328010.1016/j.seizure.2016.01.010); Oddie PD, Albert BB, Hofman PL et al (2018) Mitotane in the treatment of childhood adrenocortical carcinoma: a potent endocrine disruptor. Endocrinol Diabetes Metab Case Rep 2018:18–0059. (PMID: 301591506109212); Zatelli MC, Gentilin E, Daffara F et al (2010) Therapeutic concentrations of mitotane (o,p’-DDD) inhibit thyrotroph cell viability and TSH expression and secretion in a mouse cell line model. Endocrinology 151:2453–2461. (PMID: 2039282810.1210/en.2009-1404); van Seters AP, Moolenaar AJ (1991) Mitotane increases the blood levels of hormone-binding proteins. Acta Endocrinol 124:526–553.; Marshall JS, Tompkins LS (1968) Effect of o, p_- DDD and similar compounds on thyroxinee binding globulin. J Clin Endocrinol Metab 28:386–439. (PMID: 417108410.1210/jcem-28-3-386); Basile V, Puglisi S, Calabrese A et al (2020) Unwanted Hormonal and Metabolic Effects of Postoperative Adjuvant Mitotane Treatment for Adrenocortical Cancer. Cancers (Basel) 12:2615. (PMID: 32937772756570110.3390/cancers12092615); Hiraoka A, Kumada T, Tada T et al (2023) Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinib. Cancer Med 12:325–334. (PMID: 3566604010.1002/cam4.4854); Zhang Q, Jiao X, Lai X (2023) Clinical Characters and Influence Factors of Immune Checkpoint Inhibitor-related Thyroid Dysfunction. J Clin Endocrinol Metab 108:2916–2923. (PMID: 371834271058397810.1210/clinem/dgad260); Van Santen HM, Chemaitilly W, Meacham LR et al (2020) Endocrine Health in Childhood Cancer Survivors. Pediatr Clin N Am 67:1171–1186. (PMID: 10.1016/j.pcl.2020.08.002); van Iersel L, Xu J, Potter BS et al (2019) Clinical importance of free thyroxine concentration decline after radiotherapy for pediatric and adolescent brain tumors. J Clin Endocrinol Metab 104:4998–5007. (PMID: 3117308310.1210/jc.2019-00539); Sklar CA, Antal Z, Chemaitilly W et al (2018) Hypothalamic-pituitary and growth disorders in survivors of childhood cancer: an Endocrine Society Clinical practice guideline. J Clin Endocrinol Metab 103:2761–2784. (PMID: 2998247610.1210/jc.2018-01175); van Iersel L, Mulder RL, Denzer C et al (2022) Hypothalamic-Pituitary and Other Endocrine Surveillance Among Childhood Cancer Survivors. Endocr Rev 43:794–823. (PMID: 3496257310.1210/endrev/bnab040); Chemaitilly W, Sklar CA (2019) Childhood Cancer Treatments and Associated Endocrine Late Effects: A Concise Guide for the Pediatric Endocrinologist. Horm Res Paediatr 91:74–82. (PMID: 3040409110.1159/000493943); Filges I, Bischof-Renner A, Röthlisberger B et al (2012) Panhypopituitarism presenting as life-threatening heart failure caused by an inherited microdeletion in 1q25 including LHX4. Pediatrics 129:e529–e534. (PMID: 2223230910.1542/peds.2010-3849); Claude F, Ubertini G, Szinnai G (2022) Endocrine Disorders in Children with Brain Tumors: At Diagnosis, after Surgery, Radiotherapy and Chemotherapy. Child Basel 9:1617. (PMID: 10.3390/children9111617); Clement SC, Schouten-van Meeteren AY, Boot AM et al (2016) Prevalence and Risk Factors of Early Endocrine Disorders in Childhood Brain Tumor Survivors: A Nationwide, Multicenter Study. J Clin Oncol 34:4362–4370. (PMID: 2799821810.1200/JCO.2016.67.5025); González Briceño LG, Kariyawasam D, Samara-Boustani D et al (2022) High Prevalence of Early Endocrine Disorders After Childhood Brain Tumors in a Large Cohort. J Clin Endocrinol Metab 107:e2156–e2166. (PMID: 3491811210.1210/clinem/dgab893); Beck-Peccoz P, Rodari G, Giavoli C et al (2017) Central hypothyroidism – a neglected thyroid disorder. Nat Rev Endocrinol 13:588–598. (PMID: 2854906110.1038/nrendo.2017.47); Benvenga S, Klose M, Vita R et al (2018) Less known aspects of central hypothyroidism. J Clin Transl Endocrinol 14:25–33. (PMID: 304169726205405); Abucham J, Martins M (2024) Subclinical central hypothyroidism in patients with hypothalamic-pituitary disease: does it exist? Rev Endocr Metab Disord 25:609–618. (PMID: 3832408110.1007/s11154-024-09876-y); Portes ES, Oliveira JH, MacCagnan P et al (2000) Changes in serum thyroid hormones levels and their mechanisms during long-term growth hormone (GH) replacement therapy in GH deficient children. Clin Endocrinol (Oxf) 53:183–189. (PMID: 1093109910.1046/j.1365-2265.2000.01071.x); Leung AM, Brent GA (2016) Growth Hormone Deficiency: The Influence of Thyroid Hormone on Growth Hormone Secretion and Action. In: Cohen L (ed) Growth Hormone Deficiency. Springer, Cham. https://doi.org/10.1007/978-3-319-28038-7_4.; Welch JJG, Ames B, Cohen LE et al (2022) Management of childhood cancer survivors at risk for thyroid function abnormalities: A Delphi study. Pediatr Blood Cancer 69:e29942. (PMID: 3606960110.1002/pbc.29942); Fleseriu M, Hashim IA, Karavitaki N et al (2016) Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 101:3888–3921. (PMID: 2773631310.1210/jc.2016-2118); Howell JC, Rose SR (2019) Pituitary disease in pediatric brain tumor survivors. Expert Rev Endocrinol Metab 14:283–291. (PMID: 3113164710.1080/17446651.2019.1620599); van Maa I, Bakker B, van Santen HM et al (2022) Hormone replacement in survivors of childhood cancer and brain tumors: safety and controversies. Endocr Connect 12:e220382.; Chemaitilly W, Cohen LE, Mostoufi-Moab S et al (2018) Endocrine Late Effects in Childhood Cancer Survivors. J Clin Oncol 36:2153–2159. (PMID: 2987413010.1200/JCO.2017.76.3268); Diller L, Chow EJ, Gurney JG et al (2009) Chronic disease in the Childhood Cancer Survivor Study cohort: a review of published findings. J Clin Oncol 27:2339–2355. (PMID: 19364955267792210.1200/JCO.2008.21.1953); Çağlar AA, Oğuz A, Pınarlı FG et al (2014) Thyroid abnormalities in survivors of childhood cancer. J Clin Res Pediatr Endocrinol 6:144–1451. (PMID: 25241607429364210.4274/jcrpe.1326); Nishiyama K, Kozuka T, Higashihara T et al (1996) Acute radiation thyroiditis. Int J Radiat Oncol Biol Phys 36:1221–1224. (PMID: 898504710.1016/S0360-3016(96)00480-4); Ron E, Brenner A (2010) Non-malignant thyroid diseases after a wide range of radiation exposures. Radiat Res 174:877–888. (PMID: 21128812392778910.1667/RR1953.1); Hancock SL, Cox RS, McDougall IR (1991) Thyroid diseases after treatment of Hodgkin’s disease. N Engl J Med 325:599–605. (PMID: 186169310.1056/NEJM199108293250902); Chow EJ, Friedman DL, Stovall M et al (2009) Risk of thyroid dysfunction and subsequent thyroid cancer among survivors of acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer 53:432–437. (PMID: 19459201271336210.1002/pbc.22082); Sklar C, Whitton J, Mertens A et al (2000) Abnormalities of the thyroid in survivors of Hodgkin’s disease: data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 85:3227–3232. (PMID: 10999813); Illés A, Bíró E, Miltényi Z et al (2003) Hypothyroidism and thyroiditis after therapy for Hodgkin’s disease. Acta Haematol 109:11–17. (PMID: 1248631710.1159/000067269); Clausen CT, Hasle H, Holmqvist AS et al (2019) Hyperthyroidism as a late effect in childhood cancer survivors - an Adult Life after Childhood Cancer in Scandinavia (ALiCCS) study. Acta Oncol 58:227–231. (PMID: 3058551410.1080/0284186X.2018.1535187); Sklar C, Boulad F, Small T et al (2001) Endocrine complications of pediatric stem cell transplantation. Front Biosci 6:G17–22. (PMID: 1148747910.2741/A714); Sinha A, Abinun M, Gennery AR et al (2013) Graves’ immune reconstitution inflammatory syndrome in childhood. Thyroid 23:1010–1114. (PMID: 2355647910.1089/thy.2012.0618); Quach A, Ji L, Mishra V, Sznewajs A et al (2011) Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastoma. Pediatr Blood Cancer 56:191–201. (PMID: 2083077510.1002/pbc.22767); Drui D, Illouz F, Do Cao C et al (2018) Expert opinion on thyroid complications of new anti-cancer therapies: Tyrosine kinase inhibitors. Ann Endocrinol (Paris) 79:569–573. (PMID: 3012662610.1016/j.ando.2018.07.003); Iyer PC, Cabanillas ME, Waguespack SG et al (2018) Immune-Related Thyroiditis with Immune Checkpoint Inhibitors. Thyroid 28:1243–1251. (PMID: 30132401615735910.1089/thy.2018.0116); Children’s Oncology Group (2018) Long Term Follow-up Guidelines for Survivors od CHildhood, Adolescent and Young Adult Cancer, Version 4.0.; Clement SC, Kremer LCM, Verburg FA et al (2018) Balancing the benefits and harms of thyroid cancer surveillance in survivors of Childhood, adolescent and young adult cancer: Recommendations from the international Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium. Cancer Treat Rev 63:28–39. (PMID: 2920244510.1016/j.ctrv.2017.11.005); Francis GL, Waguespack SG, Bauer AJ et al (2015) American Thyroid Association Guidelines Task Force. Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 25:716–759. (PMID: 25900731485427410.1089/thy.2014.0460); Lebbink CA, Links TP, Czarniecka A et al (2022) 2022 European Thyroid Association Guidelines for the management of pediatric thyroid nodules and differentiated thyroid carcinoma. Eur Thyroid J 11:e220146. (PMID: 36228315971639310.1530/ETJ-22-0146); Clement SC, van Rijn RR, van Eck-Smit BL et al (2015) Long-term efficacy of current thyroid prophylaxis and future perspectives on thyroid protection during 131I-metaiodobenzylguanidine treatment in children with neuroblastoma. Eur J Nucl Med Mol Imaging 42:706–715. (PMID: 2551205610.1007/s00259-014-2967-4); Sapuppo G, Tavarelli M, Cannata E et al (2021) Risk of Benign and Malignant Thyroid Disorders in Subjects Treated for Paediatric/Adolescent Neoplasia: Role of Morphological and Functional Screening. Child (Basel) 8:767.; Baran JA, Halada S, Bauer AJ et al (2024) Thyroid Ultrasound Screening in Childhood Cancer Survivors following Radiotherapy. Horm Res Paediatr 97:243–253. (PMID: 3772236010.1159/000531241); Brignardello E, Felicetti F, Castiglione A et al (2016) Ultrasound surveillance for radiation-induced thyroid carcinoma in adult survivors of childhood cancer. Eur J Cancer 55:74–80. (PMID: 2677521310.1016/j.ejca.2015.12.006); Nikiforov YE (2006) Radiation-induced thyroid cancer: what we have learned from chernobyl. Endocr Pathol 17:307–317. (PMID: 1752547810.1007/s12022-006-0001-5); Williams D (2008) Radiation carcinogenesis: lessons from Chernobyl. Oncogene 27(Suppl 2):S9–18. (PMID: 1995618210.1038/onc.2009.349); Romei C, Ciampi R, Elisei R (2016) A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma. Nat Rev Endocrinol 12:192–202. (PMID: 2686843710.1038/nrendo.2016.11); Journy N, Indelicato DJ, Withrow DR et al (2019) Patterns of proton therapy use in pediatric cancer management in 2016: An international survey. Radiother Oncol 132:155–161. (PMID: 3041475910.1016/j.radonc.2018.10.022); Clement SC, Lebbink CA, Klein Hesselink MS et al (2020) Presentation and outcome of subsequent thyroid cancer among childhood cancer survivors compared to sporadic thyroid cancer: a matched national study. Eur J Endocrinol 183:169–180. (PMID: 3244969210.1530/EJE-20-0153); de Vathaire F, Haddy N, Allodji RS et al (2015) Thyroid Radiation Dose and Other Risk Factors of Thyroid Carcinoma Following Childhood Cancer. J Clin Endocrinol Metab 100:4282–4290. (PMID: 2632748110.1210/jc.2015-1690); Li Z, Franklin J, Zelcer S et al (2014) Ultrasound surveillance for thyroid malignancies in survivors of childhood cancer following radiotherapy: a single institutional experience, vol 24. Thyroid, pp 1796–1805.; Ho WL, Zacharin MR (2016) Thyroid carcinoma in children, adolescents and adults, both spontaneous and after childhood radiation exposure. Eur J Pediatr 175:677–683. (PMID: 2680540810.1007/s00431-016-2692-z); Agrawal C, Guthrie L, Sturm MS et al (2016) Comparison of Thyroid Nodule Prevalence by Ultrasound in Childhood Cancer Survivors With and Without Thyroid Radiation Exposure. J Pediatr Hematol Oncol 38:43–48. (PMID: 2658362310.1097/MPH.0000000000000473); Chan CM, Prager J, Travers S (2017) Pediatric Thyroid Cancer. Adv Pediatr 64:171–190. (PMID: 2868858810.1016/j.yapd.2017.03.007); Albi E, Cataldi S, Lazzarini A et al (2017) Radiation and thyroid cancer. Int J Mol Sci 18:E911. (PMID: 10.3390/ijms18050911); Sigurdson AJ, Ronckers CM, Mertens AC et al (2005) Primary thyroid cancer after a first tumor in childhood (the childhood cancer survivor study): a nested case-control study. Lancet Lond Engl 365:2014–2023. (PMID: 10.1016/S0140-6736(05)66695-0); Dracham CB, Shankar A, Madan R (2018) Radiation induced secondary malignancies: a review article. Radiat Oncol 36(2):85–94. 10.3857/ roj.2018.00290. (PMID: 10.3857/roj.2018.00290); Rizzo JD, Curtis RE, Socié G et al (2009) Solid cancers after allogeneic hematopoietic cell transplantation. Blood 113:1175–1183. (PMID: 1897141910.1182/blood-2008-05-158782); Cohen A, Rovelli A, Merlo DF et al (2007) Risk for secondary thyroid carcinoma after hematopoietic stem-cell transplantation: an EBMT late effects working party study. J Clin Oncol 25:2449–2454. (PMID: 1755795810.1200/JCO.2006.08.9276); Tonorezos ES, Barnea D, Moskowitz CS et al (2017) Screening for thyroid cancer in survivors of childhood and young adult cancer treated with neck radiation. J Cancer Surviv 11:302–308. (PMID: 2802876210.1007/s11764-016-0588-6); Veiga LH, Bhatti P, Ronckers CM et al (2012) Chemotherapy and thyroid cancer risk: a report from the childhood cancer survivor study. Cancer Epidemiol Biomarkers Prev 21:92–101. (PMID: 2202839910.1158/1055-9965.EPI-11-0576); Zubarovskaya N, Bauer D, Ronceray L et al (2022) To lighten the burden of cure: Thyroid disease in long-term survivors after TBI conditioning for paediatric ALL. Front Pediatr 9:798974. (PMID: 35127596880913610.3389/fped.2021.798974); Duarte V, Maciel J, Cavaco D et al (2022) Predictive factors for thyroid complications after radiation therapy-data from a cohort of cancer patients closely followed since they were irradiated. Clin Endocrinol (Oxf) 96:728–733. (PMID: 3497835410.1111/cen.14665); Sanders JE, Hoffmeister PA, Woolfrey AE et al (2009) Thyroid function following hematopoietic cell transplantation in children: 30 years’ experience. Blood 113:306–308. (PMID: 1883861410.1182/blood-2008-08-173005); Vivanco M, Dalle JH, Alberti C et al (2012) Malignant and benign thyroid nodules after total body irradiation preceding hematopoietic cell transplantation during childhood. Eur J Endocrinol 167:225–233. (PMID: 2261935010.1530/EJE-12-0073); Cattoni A, Molinari S, Riva B et al (2022) Thyroid function disorders and secondary cancer following haematopoietic stem cell transplantation in pediatrics: State of the art and practical recommendations for a risk-based follow-up. Front Endocrinol (Lausanne) 13:1064146. (PMID: 36619560981158610.3389/fendo.2022.1064146); Nelson AS, Ashton LJ, Vajdic CM et al (2015) Second cancers and late mortality in Australian children treated by allogeneic HSCT for haematological malignancy. Leukemia 29:441–447. (PMID: 2496201610.1038/leu.2014.203); Wijnen M, van den Heuvel-Eibrink MM, Medici M et al (2016) Risk factors for subsequent endocrine-related cancer in childhood cancer survivors. Endocr Relat Cancer 23:R299–321. (PMID: 2722993310.1530/ERC-16-0113); Martucci C, Crocoli A, De Pasquale MD et al (2022) Thyroid cancer in children: A multicenter international study highlighting clinical features and surgical outcomes of primary and secondary tumors. Front Pediatr 10:914942. (PMID: 35935364935495810.3389/fped.2022.914942); Gambale C, Rocha JV, Prete A et al (2024) Insights into Ultrasound Features and Risk Stratification Systems in Pediatric Patients with Thyroid Nodules. J Imaging 10:189. (PMID: 391949771135541510.3390/jimaging10080189); Dorffel W, Riepenhausenl M, Luders H et al (2015) Secondary malignancies following treatment for Hodgkin’s lymphoma in childhood and adolescence. Dtsch Arztebl Int 112:320–327. (PMID: 260374684455255); Finke I, Scholz-Kreisel P, Hennewig U et al (2015) Radiotherapy and subsequent thyroid cancer in German childhood cancer survivors: a nested case-control study. Radiat Oncol 10:219. (PMID: 26517987462829710.1186/s13014-015-0521-6); Paetow U, Bader P, Chemaitilly W (2020) A systematic approach to the endocrine care of survivors of pediatric hematopoietic stem cell transplantation. Cancer Metastasis Rev 39:69–78. (PMID: 3198096810.1007/s10555-020-09864-z); Atlas G, Farrell S, Zacharin M (2022) Secondary thyroid carcinoma in survivors of childhood cancer: A need to revise current screening recommendations. Clin Endocrinol (Oxf) 97:137–139. (PMID: 35460104954453910.1111/cen.14746); Furui Y, Morita D, Okura E et al (2020) Thyroid tumor surveillance using ultrasound in childhood cancer survivors. Pediatr Int 62:562–568. (PMID: 3201728410.1111/ped.14179); Oudin C, Auquier P, Bertrand Y et al (2016) Late thyroid complications in survivors of childhood acute leukemia. an L.E.A. study. Haematologica 101:747–756. (PMID: 26969082501395010.3324/haematol.2015.140053) |
| Contributed Indexing: | Keywords: Childhood cancer survivors; Hyperthyroidism; Hypothyroidism; Surveillance; Thyroid cancer; Thyroid nodules |
| Entry Date(s): | Date Created: 20260415 Latest Revision: 20260415 |
| Update Code: | 20260415 |
| DOI: | 10.1007/s40618-026-02851-1 |
| PMID: | 41984406 |
| Database: | MEDLINE |
Journal Article; Review